BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006;23:451-463. [PMID: 16441465 DOI: 10.1111/j.1365-2036.2006.02786.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 162] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25:19-37. [PMID: 17229218 DOI: 10.1111/j.1365-2036.2006.03131.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 6.2] [Reference Citation Analysis]
2 Luber AJ, Tsui CL, Heinecke GM, Lebwohl MG, Levitt JO. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. J Am Acad Dermatol 2014;70:525-32. [PMID: 24388425 DOI: 10.1016/j.jaad.2013.10.059] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
3 Rosh JR. Use of biologic agents in pediatric inflammatory bowel disease. Current Opinion in Pediatrics 2009;21:646-50. [DOI: 10.1097/mop.0b013e32832ff22c] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Moriconi F, Raddatz D, Ho NA, Yeruva S, Dudas J, Ramadori G. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis. Transl Res. 2007;150:223-232. [PMID: 17900510 DOI: 10.1016/j.trsl.2007.04.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:45-52. [PMID: 26395534 DOI: 10.1586/17474124.2015.1091308] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
6 Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther 2010;31:553-60. [PMID: 20002026 DOI: 10.1111/j.1365-2036.2009.04206.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
7 Bermejo F, San Román AL, Algaba A, Van Domselaar M, Carneros JA, Rivero M, Piqueras B, Paz Valer M. Eficacia de la premedicación con un esteroide y un antihistamínico en la prevención de reacciones infusionales por infliximab. Gastroenterología y Hepatología 2008;31:629-32. [DOI: 10.1016/s0210-5705(08)75809-6] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
8 Yudina Y, Parhamifar L, Bengtsson AM, Juhas M, Sjölander A. Regulation of the eicosanoid pathway by tumour necrosis factor alpha and leukotriene D4 in intestinal epithelial cells. Prostaglandins Leukot Essent Fatty Acids. 2008;79:223-231. [PMID: 19042113 DOI: 10.1016/j.plefa.2008.09.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
9 Agarwal A, Scott FI, Ahmad NA, Chandrasekhara V. Chronic immunosuppression does not potentiate the malignant progression of mucinous pancreatic cystic lesions. Pancreatology 2016;16:900-4. [PMID: 27424477 DOI: 10.1016/j.pan.2016.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Perrier C, Rutgeerts P. Cytokine blockade in inflammatory bowel diseases. Immunotherapy. 2011;3:1341-1352. [PMID: 22053885 DOI: 10.2217/imt.11.122] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]
11 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
12 Akimova T, Xiao H, Liu Y, Bhatti TR, Jiao J, Eruslanov E, Singhal S, Wang L, Han R, Zacharia K, Hancock WW, Beier UH. Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T-regulatory cells. Mucosal Immunol. 2014;7:1209-1220. [PMID: 24549276 DOI: 10.1038/mi.2014.10] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
13 Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19-30. [PMID: 17944997 DOI: 10.1111/j.1365-2036.2007.03553.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 4.6] [Reference Citation Analysis]
14 Bootz F, Ziffels B, Neri D. Antibody-Based Targeted Delivery of Interleukin-22 Promotes Rapid Clinical Recovery in Mice With DSS-Induced Colitis. Inflamm Bowel Dis 2016;22:2098-105. [PMID: 27482975 DOI: 10.1097/MIB.0000000000000851] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
15 Kaplan G, Panaccione R. Use of combination therapy in IBD. Inflamm Bowel Dis 2008;14 Suppl 2:S219-21. [PMID: 18816768 DOI: 10.1002/ibd.20688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Sono K, Yamada A, Yoshimatsu Y, Takada N, Suzuki Y. Factors associated with the loss of response to infliximab in patients with Crohn's disease. Cytokine 2012;59:410-6. [PMID: 22633084 DOI: 10.1016/j.cyto.2012.04.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: A review of medical therapy. World J Gastroenterol 2008; 14(3): 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 128] [Article Influence: 9.8] [Reference Citation Analysis]
18 Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OBS, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease - a nationwide cohort study. Aliment Pharmacol Ther 2013;37:214-24. [DOI: 10.1111/apt.12159] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
19 Ondas O, Ates O, Keles S, Yildirim K, Baykal O, Karamese SA, Karamese M, Uslu H, Yildirim M, Naldan ME, Ates I. Intravitreal Infliximab Injection to Treat Experimental Endophthalmitis. Eurasian J Med 2017;49:167-71. [PMID: 29123438 DOI: 10.5152/eurasianjmed.2017.17126] [Reference Citation Analysis]
20 Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010;32:384-393. [PMID: 20491747 DOI: 10.1111/j.1365-2036.2010.04360.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
21 Arantes JAV, Santos CHMD, Delfino BM, Silva BAD, Souza RMMD, Souza TMMD, Flávio ID, Ferreira CG, Cruz SBGD. Epidemiological profile and clinical characteristics of patients with intestinal inflammatory disease. Journal of Coloproctology 2021;37:273-8. [DOI: 10.1016/j.jcol.2017.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
22 Saro C, da la Coba C, Casado MA, Morales JM, Otero B. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther. 2007;26:1313-1323. [PMID: 17850419 DOI: 10.1111/j.1365-2036.2007.03507.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
23 Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, Reinisch W. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111:477-491. [PMID: 26856754 DOI: 10.1038/ajg.2016.7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 15.0] [Reference Citation Analysis]
24 Dumortier J, Lapalus MG, Guillaud O, Poncet G, Gagnieu MC, Partensky C, Scoazec JY. Everolimus for refractory Crohn's disease: a case report. Inflamm Bowel Dis. 2008;14:874-877. [PMID: 18275074 DOI: 10.1002/ibd.20395] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
25 Amre D, Amre R, Prakash S. Inflammatory bowel diseases: current treatment strategies and potential for drug delivery using artificial cell microcapsules. Artificial Cells, Cell Engineering and Therapy. Elsevier; 2007. pp. 454-68. [DOI: 10.1533/9781845693077.4.454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
27 Platt AM, Mowat AM. Mucosal macrophages and the regulation of immune responses in the intestine. Immunol Lett. 2008;119:22-31. [PMID: 18601952 DOI: 10.1016/j.imlet.2008.05.009] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 5.4] [Reference Citation Analysis]
28 Pech T, Finger T, Fujishiro J, Praktiknjo M, Ohsawa I, Abu-elmagd K, Limmer A, Hirner A, Kalff JC, Schaefer N. Perioperative Infliximab Application Ameliorates Acute Rejection Associated Inflammation After Intestinal Transplantation: Perioperative Infliximab Application Ameliorates Acute Rejection. American Journal of Transplantation 2010;10:2431-41. [DOI: 10.1111/j.1600-6143.2010.03279.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
29 Mir Subías A, García-López S, Sebastián Torres B, Ollero Domenche L, García Gámez A, Gomollón F. [Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: an infrequent but important complication of infliximab in Crohn's disease]. Gastroenterol Hepatol 2013;36:81-5. [PMID: 23218770 DOI: 10.1016/j.gastrohep.2012.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
30 Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35:821-36. [PMID: 17129815 DOI: 10.1016/j.gtc.2006.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
31 Uslu N, Usta Y, Saltik-Temizel IN, Demir H, Gürakan F, Ozen H, Yüce A. Ineffectiveness of infliximab therapy in severe infantile Crohn's disease. J Crohns Colitis 2010;4:106-9. [PMID: 21122492 DOI: 10.1016/j.crohns.2009.08.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Segarra Cantón O, Infante Pina D, Tormo Carnicé R. [Infliximab therapy for inflammatory bowel disease: seven years on]. An Pediatr (Barc) 2007;67:344-51. [PMID: 17949644 DOI: 10.1016/s1695-4033(07)70652-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Jiang XL, Cui HF. New treatments for refractory ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2011; 19(18): 1871-1873 [DOI: 10.11569/wcjd.v19.i18.1871] [Reference Citation Analysis]
34 Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:78-91. [DOI: 10.1038/ncpgasthep0695] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
35 Tursi A. Segmental Colitis Associated with Diverticulosis: Complication of Diverticular Disease or Autonomous Entity? Dig Dis Sci 2011;56:27-34. [DOI: 10.1007/s10620-010-1230-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
36 Cassano N, Guerra AP, Malara C, Loconsole F, Galluccio A, Pezza M, Vena G. Re-Induction as a Possible Alternative Modality of Dose Escalation of Infliximab: A Prospective Evaluation in a Small Series of Psoriatic Patients. Int J Immunopathol Pharmacol 2007;20:647-50. [DOI: 10.1177/039463200702000324] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
37 de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol. 2007;151:915-929. [PMID: 17502850 DOI: 10.1038/sj.bjp.0707264] [Cited by in Crossref: 386] [Cited by in F6Publishing: 370] [Article Influence: 25.7] [Reference Citation Analysis]
38 Rahier JF. Prevention and management of infectious complications in IBD. Dig Dis. 2012;30:408-414. [PMID: 22796807 DOI: 10.1159/000338143] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
39 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
40 Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439-448. [PMID: 17156147 DOI: 10.1111/j.1572-0241.2006.01010.x] [Cited by in Crossref: 189] [Cited by in F6Publishing: 189] [Article Influence: 11.8] [Reference Citation Analysis]
41 Bousquet J, Chiron R, Humbert M. Biologics in asthma: difficulties and drawbacks. Expert Opin Biol Ther 2008;8:1921-8. [PMID: 18990078 DOI: 10.1517/14712590802496928] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
42 Lin X, Zamora PO, Takahashi K, Lui Y. Alleviation of experimental ulcerative colitis with the synthetic peptide, F2A4-K-NS (Fibratide). Dig Dis Sci 2007;52:2054-62. [PMID: 17404850 DOI: 10.1007/s10620-006-9641-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
43 Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Graziani MG, Lorenzetti R, Luzza F, Paese P, Penna A, Pica R, Pranzo G, Rodinò S, Scarcelli A, Zampaletta C, Brozzi L, Cicerone C, Cocco A, De' Angelis G, Donnarumma L, Fiorella S, Iannelli C, Larussa T, Le Grazie M, Luppino I, Meucci C, FaggianI R, Pagnini C, Perazzo P, Rodriguez-Castro KI, Sacco R, Sebkova L, Serio M, De Monti A, Picchio M, Napolitano D, Schiavoni E, Turchini L, Scaldaferri F, Pugliese D, Guidi L, Laterza L, Privitera G, Pizzoferrato M, Lopetuso LR, Armuzzi A, Elisei W, Maconi G, Papa A. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. Expert Opin Biol Ther 2021;:1-8. [PMID: 34904510 DOI: 10.1080/14712598.2022.2007881] [Reference Citation Analysis]
44 Sauzullo I, Mengoni F, Marocco R, Potenza C, Skroza N, Tieghi T, Lichtner M, Vullo V, Mastroianni C. Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis. Br J Dermatol 2013;169:1133-40. [DOI: 10.1111/bjd.12544] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
45 Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, Legaki E, Romanos I, Mouzas I, Koutroubakis IE. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab. Eur J Gastroenterol Hepatol 2019;31:187-91. [PMID: 30543573 DOI: 10.1097/MEG.0000000000001332] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Slevin SM, Egan LJ. New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:2909-2920. [PMID: 26348448 DOI: 10.1097/mib.0000000000000533] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
47 Chakilam S, Gandesiri M, Rau TT, Agaimy A, Vijayalakshmi M, Ivanovska J, Wirtz RM, Schulze-Luehrmann J, Benderska N, Wittkopf N, Chellappan A, Ruemmele P, Vieth M, Rave-Fränk M, Christiansen H, Hartmann A, Neufert C, Atreya R, Becker C, Steinberg P, Schneider-Stock R. Death-associated protein kinase controls STAT3 activity in intestinal epithelial cells. Am J Pathol 2013;182:1005-20. [PMID: 23438478 DOI: 10.1016/j.ajpath.2012.11.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
48 Yi L, Luo J, Xie B, Liu J, Wang J, Liu L, Wang P, Zhou H, Dong Y. α7 Nicotinic Acetylcholine Receptor is a Novel Mediator of Sinomenine Anti-Inflammation Effect in Macrophages Stimulated by Lipopolysaccharide. Shock 2015;44:188-95. [DOI: 10.1097/shk.0000000000000389] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
49 Park KT, Sin A, Wu M, Bass D, Bhattacharya J. Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience. Inflamm Bowel Dis. 2014;20:1242-1249. [PMID: 24846718 DOI: 10.1097/mib.0000000000000061] [Cited by in Crossref: 34] [Cited by in F6Publishing: 10] [Article Influence: 4.9] [Reference Citation Analysis]
50 Moffatt DC, Bernstein CN. Drug therapy for inflammatory bowel disease in pregnancy and the puerperium. Best Practice & Research Clinical Gastroenterology 2007;21:835-47. [DOI: 10.1016/j.bpg.2007.05.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
51 Lichtenstein GR, Cohen R, Yamashita B, Diamond RH. Quality of Life After Proctocolectomy With Ileoanal Anastomosis for Patients With Ulcerative Colitis: . Journal of Clinical Gastroenterology 2006;40:669-77. [DOI: 10.1097/00004836-200609000-00002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
52 Rosh JR. Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:302-7. [DOI: 10.1007/s11894-008-0060-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Pressman AR, Hutfless S, Velayos F, Fireman B, Lewis JD, Allison J, Abramson O, Herrinton LJ. Patterns of infliximab use among Crohn's disease patients in a community setting. Inflamm Bowel Dis 2008;14:1265-72. [PMID: 18452199 DOI: 10.1002/ibd.20483] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
54 Gisbert JP, Panés J. Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review. Am J Gastroenterol 2009;104:760-7. [DOI: 10.1038/ajg.2008.88] [Cited by in Crossref: 344] [Cited by in F6Publishing: 350] [Article Influence: 26.5] [Reference Citation Analysis]
55 Vena GA, Cassano N. Anti-tumor necrosis factor therapies for psoriasis. Expert Review of Dermatology 2014;2:335-49. [DOI: 10.1586/17469872.2.3.335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
56 Kotze PG, Akiyoshi FK, Luvizotto M, Olandoski M, Kotze LMDS, Coy CSR. Comparative analysis of adverse events between infliximab and adalimumab in Crohn's disease management: a Brazilian single-centre experience. Journal of Coloproctology 2021;33:033-8. [DOI: 10.1016/j.jcol.2013.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Puig L, Carrascosa J, Daudén E, Sánchez-carazo J, Ferrándiz C, Sánchez-regaña M, García-bustinduy M, Bordas X, Moreno J, Hernanz J, Laguarda S, García-patos V. Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. Actas Dermo-Sifiliográficas (English Edition) 2009;100:386-413. [DOI: 10.1016/s1578-2190(09)70086-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Goettel JA, Liang D, Hilliard VC, Edelblum KL, Broadus MR, Gould KL, Hanks SK, Polk DB. KSR1 is a functional protein kinase capable of serine autophosphorylation and direct phosphorylation of MEK1. Exp Cell Res 2011;317:452-63. [PMID: 21144847 DOI: 10.1016/j.yexcr.2010.11.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
59 Barnhill MS, Steinberg JM, Jennings JJ, Lewis JH. Hepatotoxicty of Agents Used in the Management of Inflammatory Bowel Disease: a 2020 Update. Curr Gastroenterol Rep 2020;22:47. [PMID: 32671616 DOI: 10.1007/s11894-020-00781-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
60 Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Kouroumalis EA. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease: . European Journal of Gastroenterology & Hepatology 2007;19:789-94. [DOI: 10.1097/meg.0b013e3282202bca] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
61 Papamichael K, Archavlis E, Lariou C, Tsigka A, Mantzaris GJ. Granular cell tumour in a patient with Crohn’s disease treated with infliximab: coincidence or causal relationship? European Journal of Gastroenterology & Hepatology 2012;24:857-9. [DOI: 10.1097/meg.0b013e3283530999] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
62 McConnell J, Parvulescu-Codrea S, Behm B, Hill B, Dunkle E, Finke K, Snyder K, Tuskey A, Cox D, Woodward B. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness. World J Gastrointest Pharmacol Ther 2012; 3(5): 74-82 [PMID: 23515325 DOI: 10.4292/wjgpt.v3.i5.74] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
63 Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
64 Kroser J, Srinivasan R. Drug Therapy of Inflammatory Bowel Disease in Fertile Women. Am J Gastroenterology 2006;101:S633-9. [DOI: 10.1111/j.1572-0241.2006.00961.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
65 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intest Res 2018;16:4-16. [PMID: 29422793 DOI: 10.5217/ir.2018.16.1.4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
66 Yang Y, Yi L, Wang Q, Xie B, Dong Y, Sha C. Anti-inflammatory effects of physalin E from Physalis angulata on lipopolysaccharide-stimulated RAW 264.7 cells through inhibition of NF-κB pathway. Immunopharmacology and Immunotoxicology 2017;39:74-9. [DOI: 10.1080/08923973.2017.1282514] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
67 Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study. Aliment Pharmacol Ther 2012;35:1301-9. [PMID: 22506582 DOI: 10.1111/j.1365-2036.2012.05099.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
68 Hanauer SB. Biologic therapy for inflammatory bowel disease comes of age. Curr Gastroenterol Rep 2007;9:485-8. [DOI: 10.1007/s11894-007-0064-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
69 Dalaker M, Bonesrønning JH. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J Eur Acad Dermatol Venereol 2009;23:277-82. [PMID: 19207642 DOI: 10.1111/j.1468-3083.2008.03039.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
70 Veres G, Baldassano RN, Mamula P. Infliximab therapy for pediatric Crohn's disease. Expert Opinion on Biological Therapy 2007;7:1869-80. [DOI: 10.1517/14712598.7.12.1869] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
71 Lautenschläger C, Schmidt C, Fischer D, Stallmach A. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev. 2014;71:58-76. [PMID: 24157534 DOI: 10.1016/j.addr.2013.10.001] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 13.6] [Reference Citation Analysis]
72 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699-1708. [PMID: 25406728 DOI: 10.1517/14740338.2014.973399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
73 González-Lama Y, Vera MI, Calvo M, Abreu L. [Markers of the course of inflammatory bowel disease treated with immunomodulators or biological agents]. Gastroenterol Hepatol 2010;33:449-60. [PMID: 20122758 DOI: 10.1016/j.gastrohep.2009.11.005] [Reference Citation Analysis]
74 Rosenbach Y, Hartman C, Shapiro R, Hirsch A, Avitzur Y, Shamir R. Adalimumab treatment in children with refractory Crohn’s disease. Dig Dis Sci. 2010;55:747-753. [PMID: 19333754 DOI: 10.1007/s10620-009-0791-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
75 Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Dig Dis Sci. 2015;60:951-956. [PMID: 25326115 DOI: 10.1007/s10620-014-3392-z] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 11.1] [Reference Citation Analysis]
76 Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A. Infliximab in Crohn's disease: early and long-term treatment. Digestive and Liver Disease 2008;40:S271-9. [DOI: 10.1016/s1590-8658(08)60537-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
77 Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol 2008; 14(43): 6641-6647 [PMID: 19034966 DOI: 10.3748/wjg.14.6641] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
78 Sales-Campos H, Basso PJ, Alves VB, Fonseca MT, Bonfá G, Nardini V, Cardoso CR. Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res. 2015;48:96-107. [PMID: 25466162 DOI: 10.1590/1414-431x20143774] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
79 Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 2007;56:1181-3. [PMID: 17698862 DOI: 10.1136/gut.2006.115980] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
80 Díez M, Sánchez E, García López S, Teresa Arroyo M, Gomollón F. Tratamiento con infliximab en la colitis ulcerosa: experiencia inicial en dos centros de referencia. Gastroenterología y Hepatología 2007;30:449-53. [DOI: 10.1157/13110489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
81 Reguia?? Z, Grange F. The Role of Anti-Tumor Necrosis Factor-?? Therapy in Pyoderma Gangrenosum Associated with Inflammatory Bowel Disease: . American Journal of Clinical Dermatology 2007;8:67-77. [DOI: 10.2165/00128071-200708020-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
82 Wyneski MJ, Green A, Kay M, Wyllie R, Mahajan L. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2008;47:19-25. [PMID: 18607264 DOI: 10.1097/mpg.0b013e318174e886] [Cited by in Crossref: 40] [Cited by in F6Publishing: 6] [Article Influence: 2.9] [Reference Citation Analysis]
83 Taxonera C, Olivares D, Mendoza JL, Díaz-Rubio M, Rey E. Need for infliximab dose intensification in Crohn’s disease and ulcerative colitis. World J Gastroenterol 2014; 20(27): 9170-9177 [PMID: 25083091 DOI: 10.3748/wjg.v20.i27.9170] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
84 Levin EC, Gupta R, Brown G, Malakouti M, Koo J. Biologic fatigue in psoriasis. Journal of Dermatological Treatment 2013;25:78-82. [DOI: 10.3109/09546634.2013.826341] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
85 M.chaparro, Martínez-montiel P, Van Domselaar M, Bermejo F, Pérez-calle J, Casis B, Román AL, Algaba A, Maté J, Gisbert J. Intensification of infliximab therapy in Crohn's disease: Efficacy and safety. Journal of Crohn's and Colitis 2012;6:62-7. [DOI: 10.1016/j.crohns.2011.07.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
86 Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2034-2042. [PMID: 22294550 DOI: 10.1002/ibd.22901] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
87 González-lama Y, Taxonera C, López-sanromán A, Pérez-calle JL, Bermejo F, Pajares R, Mcnicholl AG, Opio V, Mendoza JL, López P, Algaba A, Estelles J, Barbero A, Mendoza J, Maté J, Gisbert JP. Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. European Journal of Gastroenterology & Hepatology 2012;24:1086-91. [DOI: 10.1097/meg.0b013e3283556db5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
88 de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm. 2015;2015:493012. [PMID: 26339135 DOI: 10.1155/2015/493012] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 11.9] [Reference Citation Analysis]
89 Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15(17): 2067-2073 [PMID: 19418577 DOI: 10.3748/wjg.15.2067] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 67] [Article Influence: 5.3] [Reference Citation Analysis]
90 Yang Y, Yi L, Wang Q, Xie B, Sha C, Dong Y. Physalin B Suppresses Inflammatory Response to Lipopolysaccharide in RAW264.7 Cells by Inhibiting NF- κ B Signaling. Journal of Chemistry 2018;2018:1-6. [DOI: 10.1155/2018/7943140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
92 Alhagamhmad MH, Day AS, Lemberg DA, Leach ST. An update of the role of nutritional therapy in the management of Crohn’s disease. J Gastroenterol. 2012;47:872-882. [PMID: 22699323 DOI: 10.1007/s00535-012-0617-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
93 Suzuki Y, Matsui T, Ito H, Ashida T, Nakamura S, Motoya S, Matsumoto T, Sato N, Ozaki K, Watanabe M, Hibi T. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohnʼs Disease: A Prospective Clinical Trial. Inflammatory Bowel Diseases 2015;21:2114-22. [DOI: 10.1097/mib.0000000000000475] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
94 Herfarth H. Infliximab in Crohnʼs disease: TREAT your friend as if he might become an enemy?: . Inflammatory Bowel Diseases 2007;13:933-4. [DOI: 10.1002/ibd.20120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
95 Sandborn WJ, Rutgeerts P, Colombel JF, Ghosh S, Petryka R, Sands BE, Mitra P, Luo A. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. J Crohns Colitis 2017;11:811-9. [PMID: 28333187 DOI: 10.1093/ecco-jcc/jjx005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
96 Herfarth H. Are we ready for top-down therapy for inflammatory bowel diseases: con. Expert Review of Gastroenterology & Hepatology 2014;1:249-55. [DOI: 10.1586/17474124.1.2.249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
97 Heetun ZS, Byrnes C, Neary P, O’morain C. Review article: reproduction in the patient with inflammatory bowel disease: REVIEW: REPRODUCTION AND INFLAMMATORY BOWEL DISEASE. Alimentary Pharmacology & Therapeutics 2007;26:513-33. [DOI: 10.1111/j.1365-2036.2007.03397.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
98 Puig L, Carrascosa J, Daudén E, Sánchez-carazo J, Ferrándiz C, Sánchez-regaña M, García-bustinduy M, Bordas X, Moreno J, Hernanz J, Laguarda S, García-patos V. Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. Actas Dermo-Sifiliográficas 2009;100:386-413. [DOI: 10.1016/s0001-7310(09)71257-8] [Cited by in Crossref: 71] [Article Influence: 5.5] [Reference Citation Analysis]
99 Gisbert JP, Gomollón F. [Common errors in the management of the seriously ill patient with inflammatory bowel disease]. Gastroenterol Hepatol 2007;30:294-314. [PMID: 17493441 DOI: 10.1157/13101982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
100 O'Sullivan M. Symposium on 'The challenge of translating nutrition research into public health nutrition'. Session 3: Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on 'Nutrition and autoimmune disease'. Nutrition in Crohn's disease. Proc Nutr Soc. 2009;68:127-134. [PMID: 19208269 DOI: 10.1017/s0029665109001025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
101 Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu P, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang S. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment: AOCC & APAGE consensus on TB in IBD-Part 1. Journal of Gastroenterology and Hepatology 2018;33:20-9. [DOI: 10.1111/jgh.14019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Juanola O, Moratalla A, Gutiérrez A, Sempere L, Zapater P, Giménez P, Almenta I, Peiró G, González-navajas JM, Such JF, Francés R. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn’s disease. J Gastroenterol 2015;50:758-68. [DOI: 10.1007/s00535-014-1020-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
103 Burke JP, Ferrante M, Dejaegher K, Watson RW, Docherty NG, De Hertogh G, Vermeire S, Rutgeerts P, D'Hoore A, Penninckx F, Geboes K, Van Assche G, O'Connell PR. Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflamm Bowel Dis 2008;14:1197-204. [PMID: 18452219 DOI: 10.1002/ibd.20482] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
104 Caprilli R, Angelucci E, Clemente V. Recent advances in the management of Crohn's disease. Digestive and Liver Disease 2008;40:709-16. [DOI: 10.1016/j.dld.2008.02.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
105 Petryszyn PW, Paradowski L. Economic implications of biological therapy for Crohn's disease. Prz Gastroenterol 2015;10:197-202. [PMID: 26759625 DOI: 10.5114/pg.2015.55749] [Reference Citation Analysis]
106 Cucchiara S, Escher JC, Hildebrand H, Amil-dias J, Stronati L, Ruemmele FM. Pediatric Inflammatory Bowel Diseases and the Risk of Lymphoma: Should We Revise Our Treatment Strategies? Journal of Pediatric Gastroenterology & Nutrition 2009;48:257-67. [DOI: 10.1097/mpg.0b013e31818cf555] [Cited by in Crossref: 33] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
107 Wei JP, Wu XY, Gao SY, Chen QY, Liu T, Liu G. Misdiagnosis and Mistherapy of Crohn's Disease as Intestinal Tuberculosis: Case Report and Literature Review. Medicine (Baltimore) 2016;95:e2436. [PMID: 26735549 DOI: 10.1097/MD.0000000000002436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
108 Büning J, Fellermann K. [Intensive care and inflammatory bowel diseases (IBD). The severe and fulminant flare]. Internist (Berl) 2011;52:833-40. [PMID: 21660632 DOI: 10.1007/s00108-010-2797-9] [Reference Citation Analysis]
109 Stoppino LP, Della Valle N, Rizzi S, Cleopazzo E, Centola A, Iamele D, Bristogiannis C, Stoppino G, Vinci R, Macarini L. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers. BMC Med Imaging 2016;16:37. [PMID: 27149857 DOI: 10.1186/s12880-016-0139-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
110 Katz JA. Management of inflammatory bowel disease in adults. J Dig Dis 2007;8:65-71. [PMID: 17532817 DOI: 10.1111/j.1443-9573.2007.00287.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
111 López San Román A, Rivero Fernández M. Estado actual del tratamiento de la enfermedad inflamatoria intestinal. Revista Clínica Española 2007;207:298-300. [DOI: 10.1157/13106853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
112 Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Scand J Gastroenterol 2016;51:1062-8. [PMID: 27002981 DOI: 10.3109/00365521.2016.1149883] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
113 Paredes JM, Ripollés T, Cortés X, Martínez MJ, Barrachina M, Gómez F, Moreno-Osset E. Abdominal sonographic changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's Disease. Dig Dis Sci 2010;55:404-10. [PMID: 19267199 DOI: 10.1007/s10620-009-0759-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
114 Quetglas EG, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M, Danese S. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol 2015;71:773-99. [PMID: 26008212 DOI: 10.1007/s00228-015-1862-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
115 Moss AC, Kim KJ, Fernandez-Becker N, Cury D, Cheifetz AS. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci. 2010;55:1413-1420. [PMID: 19533357 DOI: 10.1007/s10620-009-0856-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
116 Shelton E, Chaudrey K, Sauk J, Khalili H, Masia R, Nguyen DD, Yajnik V, Ananthakrishnan AN. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41:972-979. [PMID: 25756190 DOI: 10.1111/apt.13159] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
117 Varga C, Laszlo F, Fritz P, Cavicchi M, Lamarque D, Horvath K, Posa A, Berko A, Whittle BJ. Modulation by heme and zinc protoporphyrin of colonic heme oxygenase-1 and experimental inflammatory bowel disease in the rat. Eur J Pharmacol 2007;561:164-71. [PMID: 17292349 DOI: 10.1016/j.ejphar.2006.12.022] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
118 Blattner CM, Chaudhari SP, Young J 3rd, Murase JE. A dermatologist guide to immunogenicity. Int J Womens Dermatol 2016;2:77-84. [PMID: 28492015 DOI: 10.1016/j.ijwd.2016.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
119 Markowitz J. Current treatment of inflammatory bowel disease in children. Digestive and Liver Disease 2008;40:16-21. [DOI: 10.1016/j.dld.2007.07.167] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
120 Olsen T, Cui G, Goll R, Husebekk A, Florholmen J. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol. 2009;44:727-735. [PMID: 19294580 DOI: 10.1080/00365520902803507] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
121 Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011;7:55-63. [PMID: 21162650 DOI: 10.1586/eci.10.90] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 6.9] [Reference Citation Analysis]
122 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf 2014. [DOI: 10.1517/14740338.2015.973399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
123 Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009;15:1264-1275. [PMID: 19235918 DOI: 10.1002/ibd.20899] [Cited by in Crossref: 96] [Cited by in F6Publishing: 89] [Article Influence: 7.4] [Reference Citation Analysis]
124 Sciaudone G, Pellino G, Riegler G, Selvaggi F. Infliximab in Drug-Naïve Patients with Failed Ileorectal Anastomosis for Crohn’s Disease: A New Chance for Sparing the Rectum. Eur Surg Res 2011;46:163-8. [DOI: 10.1159/000324398] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
125 Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn’s disease: REVIEW: MAINTAINING REMISSION IN CROHN’S DISEASE. Alimentary Pharmacology & Therapeutics 2008;27:11-8. [DOI: 10.1111/j.1365-2036.2007.03536.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
126 Papay P, Primas C, Eser A, Novacek G, Winkler S, Frantal S, Angelberger S, Mikulits A, Dejaco C, Kazemi-shirazi L, Vogelsang H, Reinisch W. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors. Aliment Pharmacol Ther 2012;36:858-65. [DOI: 10.1111/apt.12037] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
127 Hayek AJ, Pfanner TP, White HD. Inflammatory bowel disease of the lung: The role of infliximab? Respir Med Case Rep 2015;15:85-8. [PMID: 26236612 DOI: 10.1016/j.rmcr.2015.05.012] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
128 Ramos GP, Stroh G, Al-Bawardy B, Faubion WA, Papadakis KA, Escalante P. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflamm Bowel Dis 2018;24:2272-7. [PMID: 29718223 DOI: 10.1093/ibd/izy133] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
129 Barbato M, Curione M, Viola F, Versacci P, Parisi F, Amato S, Cucchiara S. Cardiac involvement in children with IBD during infliximab therapy: . Inflammatory Bowel Diseases 2006;12:828-9. [DOI: 10.1097/00054725-200608000-00021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
130 Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, Domènech E, Eliakim R, Eser A, Frater J. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47-91. [PMID: 21172250 DOI: 10.1016/j.crohns.2009.02.010] [Cited by in Crossref: 353] [Cited by in F6Publishing: 316] [Article Influence: 27.2] [Reference Citation Analysis]
131 Whittle BJ, Varga C, Berko A, Horvath K, Posa A, Riley JP, Lundeen KA, Fourie AM, Dunford PJ. Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol 2008;153:983-91. [PMID: 18157165 DOI: 10.1038/sj.bjp.0707645] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
132 Jwa YJ, Kim N, Park HJ, Park JS, Bae WK, Kim K, Lee JS, Moon YS. A Case of Psoriasis Induced by Infliximab Treatment for Crohn's Disease. Korean J Gastroenterol 2010;56:324. [DOI: 10.4166/kjg.2010.56.5.324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
133 Zhang QW, Shen J, Zheng Q, Ran ZH. Loss of response to scheduled infliximab therapy for Crohn's disease in adults: A systematic review and meta‐analysis. J Dig Dis 2019;20:65-72. [DOI: 10.1111/1751-2980.12698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
134 Allez M. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases]. Gastroenterol Clin Biol 2008;32:467-77. [PMID: 18448294 DOI: 10.1016/j.gcb.2008.03.002] [Reference Citation Analysis]
135 Meuwis MA, Fillet M, Lutteri L, Marée R, Geurts P, de Seny D, Malaise M, Chapelle JP, Wehenkel L, Belaiche J. Proteomics for prediction and characterization of response to infliximab in Crohn’s disease: a pilot study. Clin Biochem. 2008;41:960-967. [PMID: 18489908 DOI: 10.1016/j.clinbiochem.2008.04.021] [Cited by in Crossref: 46] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
136 Gupta SR, Crandall WV, Donegan A, Johnson M, Drobnic B, Oates M, Boyle B, Maltz RM, Dotson JL. A Quality Improvement Approach to External Infliximab Infusions in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2019;69:544-50. [DOI: 10.1097/mpg.0000000000002422] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
137 Manthey C, Lohse AW, Pace A. Case report of aseptic meningitis in a patient with Crohnʼs disease under infliximab therapy: . Inflammatory Bowel Diseases 2011;17:E10. [DOI: 10.1002/ibd.21324] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
138 Ebada MA, Elmatboly AM, Ali AS, Ibrahim AM, Fayed N, Faisal AF, Alkanj S. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease. Int J Colorectal Dis 2019;34:1633-52. [DOI: 10.1007/s00384-019-03354-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
139 Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res 2018;11:215-26. [PMID: 29844695 DOI: 10.2147/JIR.S165330] [Cited by in Crossref: 58] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
140 James DG, Stone CD, Wang HL, Stenson WF. Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006;12:573-80. [PMID: 16804394 DOI: 10.1097/01.MIB.0000225333.83861.16] [Cited by in Crossref: 37] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
141 Ashraf-Benson S, Wall GC, Veach LA. Serum sickness-like reaction associated with efalizumab. Ann Pharmacother 2009;43:383-6. [PMID: 19193578 DOI: 10.1345/aph.1L495] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
142 Taxonera C, Rodrigo L, Casellas F, Calvet X, Gómez-Camacho F, Ginard D, Castro M, Castro L, Ponce M, Martínez-Montiel P, Ricart E, Gisbert JP, López-San Román A, Morales JM, Casado MA. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. J Clin Gastroenterol 2009;43:950-6. [PMID: 19448569 DOI: 10.1097/MCG.0b013e3181986917] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
143 Chang MI, Cohen BL, Greenstein AJ. A review of the impact of biologics on surgical complications in Crohn's disease. Inflamm Bowel Dis 2015;21:1472-7. [PMID: 25811432 DOI: 10.1097/MIB.0000000000000362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
144 Shigemori S, Shimosato T. Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases. Front Immunol 2017;8:22. [PMID: 28179904 DOI: 10.3389/fimmu.2017.00022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
145 Winter TA, Sandborn WJ, de Villiers WJ, Schreiber S. Treatment of Crohn’s disease with certolizumab pegol. Expert Review of Clinical Immunology 2014;3:683-94. [DOI: 10.1586/1744666x.3.5.683] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
146 Wang L, Bai AP. Biological therapies for inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2010; 18(2): 107-112 [DOI: 10.11569/wcjd.v18.i2.107] [Reference Citation Analysis]
147 Antakia R, Shorthouse AJ, Robinson K, Lobo AJ. Combined modality treatment for complex fistulating perianal Crohn’s disease. Colorectal Dis. 2013;15:210-216. [PMID: 22672653 DOI: 10.1111/j.1463-1318.2012.03124.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
148 Leso V, Leggio L, Armuzzi A, Gasbarrini G, Gasbarrini A, Addolorato G. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update: . European Journal of Gastroenterology & Hepatology 2010;22:779-86. [DOI: 10.1097/meg.0b013e328331b654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
149 González-lama Y, López-san Román A, Marín-jiménez I, Casis B, Vera I, Bermejo F, Lázaro Pérez-calle J, Taxonera C, Martínez-silva F, Menchén L, Martínez-montiel P, Calvo M, Antonio Carneros J, López P, Luis Mendoza J, María Milicua J, Huerta A, Sánchez F, Abreu L, López-palacios N, Maté J, Gisberta JP. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterología y Hepatología 2008;31:421-6. [DOI: 10.1157/13125587] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
150 Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis. 2008;14:554-565. [PMID: 17973299 DOI: 10.1002/ibd.20301] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 5.7] [Reference Citation Analysis]
151 Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol. 2012;24:1078-1085. [PMID: 22647738 DOI: 10.1097/meg.0b013e32835558cf] [Cited by in Crossref: 47] [Cited by in F6Publishing: 12] [Article Influence: 5.2] [Reference Citation Analysis]
152 Kotze PG, Albuquerque ICD, Moraes AC, Vieira A, Souza FD. Análise de custo-minimização entre o Infliximabe (IFX) e o Adalimumabe (ADA) no tratamento da doença de Crohn (DC). Rev bras colo-proctol 2009;29:158-68. [DOI: 10.1590/s0101-98802009000200002] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
153 Coenen S, Weyts E, Jorissen C, De Munter P, Noman M, Ballet V, Vermeire S, Van Assche G, Ferrante M. Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:318-324. [PMID: 28079621 DOI: 10.1097/mib.0000000000001013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
154 Xu L, Zhang T, Cui B, He Z, Xiang J, Long C, Peng Z, Li P, Huang G, Ji G, Zhang F. Clinical efficacy maintains patients' positive attitudes toward fecal microbiota transplantation. Medicine (Baltimore). 2016;95:e4055. [PMID: 27472679 DOI: 10.1097/md.0000000000004055] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
155 Liu R, Guo Z, Cao L, Wang Z, Gong J, Li Y, Zhu W. Profile of Consecutive Fecal Calprotectin Levels in the Perioperative Period and Its Predictive Capacity for Early Endoscopic Recurrence in Crohn's Disease. Dis Colon Rectum 2019;62:318-26. [PMID: 30451756 DOI: 10.1097/DCR.0000000000001263] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
156 Vena G, Loconsole F, Mastrandrea V, Buquicchio R, Cassano N. Therapeutic hotline: Re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab: a retrospective analysis. Dermatol Ther 2010;23:199-202. [PMID: 20415828 DOI: 10.1111/j.1529-8019.2010.01315.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
157 Jiang W, Zhang SC. New strategies in therapy for inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2008; 16(22): 2497-2502 [DOI: 10.11569/wcjd.v16.i22.2497] [Reference Citation Analysis]
158 Abe Y, Murano M, Murano N, Morita E, Inoue T, Kawakami K, Ishida K, Kuramoto T, Kakimoto K, Okada T, Narabayashi K, Umegaki E, Higuchi K. Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis. Dig Dis Sci 2012;57:335-44. [PMID: 21909991 DOI: 10.1007/s10620-011-1879-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
159 Cozijnsen M, Duif V, Kokke F, Kindermann A, van Rheenen P, de Meij T, Schaart M, Damen G, Norbruis O, Pelleboer R, Van den Neucker A, van Wering H, Hummel T, Oudshoorn J, Escher J, de Ridder L. Adalimumab Therapy in Children With Crohn Disease Previously Treated With Infliximab. Journal of Pediatric Gastroenterology & Nutrition 2015;60:205-10. [DOI: 10.1097/mpg.0000000000000589] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
160 Wilson DC, Thomas AG, Croft NM, Newby E, Akobeng AK, Sawczenko A, Fell JM, Murphy MS, Beattie RM, Sandhu BK. Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2010;50 Suppl 1:S14-S34. [PMID: 20081542 DOI: 10.1097/mpg.0b013e3181c92caa] [Cited by in Crossref: 37] [Cited by in F6Publishing: 14] [Article Influence: 4.1] [Reference Citation Analysis]
161 Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Ricciardelli C, Zampaletta C, Elisei W, Picchio M. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. Ann Gastroenterol 2019;32:392-9. [PMID: 31263362 DOI: 10.20524/aog.2019.0377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
162 Gonvers J, Juillerat P, Mottet C, Pittet V, Felley C, Vader J, Michetti P, Froehlich F. Maintenance of Medically Induced Remission of Crohn’s Disease. Digestion 2008;76:116-29. [DOI: 10.1159/000111026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
163 Vilar P, de Carpi JM, Acuña CE, Masiques ML. Infliximab in paediatric inflammatory bowel disease. Journal of Crohn's and Colitis 2007;1:2-9. [DOI: 10.1016/j.crohns.2007.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
164 Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFα therapy to treat Crohn's disease. Expert Opin Drug Saf 2015;14:31-44. [PMID: 25400161 DOI: 10.1517/14740338.2015.976610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
165 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]